Measuring Biological Response to Curcumin
Name of the Trial
Why This Trial Is Important
Microscopic lesions in the lining of the colon called aberrant crypt foci (ACF) are thought to be precursors of colon polyps and, ultimately, malignant tumors. ACF lesions typically display biomarkers that may indicate precancerous development. In this trial, researchers are exploring the ability of a substance called curcumin to affect these biomarkers and possibly stop the progression to cancer. Curcumin is a component of turmeric, a spice commonly used in curry powder.
Doctors are interested in determining whether curcumin supplements taken for 30 days can help reduce the levels of precancerous biomarkers in the ACF of smokers who have eight or more lesions. Smoking is a known risk factor for colon cancer, and studies suggest that as many as 80 percent of smokers have ACF lesions.
"Though it has been used for centuries in traditional medicine, we're very early in the clinical development of curcumin as a chemopreventive agent," Dr. Meyskens said. "This trial is a proof-of-principle study to see if curcumin really can affect the relevant biomarkers in humans. If it does, we can then design a larger cancer prevention trial based on demonstrated biological response rather than on results from epidemiological studies."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.